FDA Opens Applications for Expedited IND Pilot to Speed Up First-in-Human Trials
The US FDA has finalised the design of its Expedited Investigational New Drug (IND) Pilot and is accepting applications until 30 October 2026.
The pilot pairs drug developers with qualified research institutions that have the scientific expertise to prepare IND applications. The goal is to shorten the time from identifying a drug candidate to starting the first clinical trial in humans, which the FDA says can currently take up to two years in the US. The pilot is part of the US health department's Operation TrialBlazer.
Key points
- Applications are open until 30 October 2026.
- Drug companies are partnered with qualified research institutions.
- Aims to speed up both IND preparation and trial start-up after FDA clearance.
- Part of the US Operation TrialBlazer programme.
What it means for you
This is a US regulatory initiative with no direct effect on practice in Pakistan, but it reflects a global push to speed up early-phase drug development.
FDA Launches Expedited IND Pilot, Begins Accepting Applications
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.